Contribute Try STAT+ Today

WASHINGTON — Biogen’s expecting to make billions from its newly approved Alzheimer’s drug Aduhelm. But it won’t be the only one making money: the complex brain scans that help doctors decide whether a patient is a good fit for the pricey therapy will also bring in money for PET scan manufacturers and imaging drug makers, too.

If the use of those scans skyrockets, it’ll open up a new market for the companies that make the machines and the drug companies that manufacture the imaging drugs needed for those screenings.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment